Literature DB >> 4029553

Protection of liver cells from experimentally induced liver cell injury by glycyrrhizin.

Y Mizoguchi, H Katoh, H Tsutsui, S Yamamoto, S Morisawa.   

Abstract

Liver cell damage is induced when isolated liver cells coated with specific antibody against the liver cell membrane are cultured with peripheral blood mononuclear cells. Although this antibody-dependent cell-mediated cytotoxicity (ADCC) was induced by closed contact of effector cells with targets via specific antibody, a cytotoxic factor or factors causing inhibition of protein synthesis in liver cells was detected in the culture supernatant of the ADCC reaction. Similarly, peritoneal exudate macrophages activated by endotoxin lipopolysaccharide (LPS) also had cytotoxic effects on isolated liver cells by producing a cytotoxic substance or substances. These liver cell injuries caused by either ADCC or activated macrophage culture supernatants were significantly reduced by pretreatment of the isolated liver cells with glycyrrhizin before the addition of the cytotoxic culture supernatants. These results suggest that glycyrrhizin may protect liver cells from immunological injuries.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029553     DOI: 10.1007/bf02776671

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  12 in total

1.  The antiinflammatory activity of glycyrrhetinic acid and derivatives.

Authors:  R S FINNEY; G F SOMERS
Journal:  J Pharm Pharmacol       Date:  1958-10       Impact factor: 3.765

2.  Study on the corticoid-like action of glycyrrhizine and the mechanism of its action.

Authors:  A KUMAGAI; S YANO; M OTOMO
Journal:  Endocrinol Jpn       Date:  1957-03

3.  In vitro studies on IgG-mediated lymphocyte cytotoxicity in chronic active liver disease.

Authors:  H Kawanishi
Journal:  Gastroenterology       Date:  1977-09       Impact factor: 22.682

4.  An improved method for the isolation of hepatocytes from liver slices. Selective removal of Trypan blue-dyeable cells.

Authors:  P Bellemann; R Gebhardt; D Mecke
Journal:  Anal Biochem       Date:  1977-08       Impact factor: 3.365

5.  Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis.

Authors:  A L Eddleston; R Williams
Journal:  Lancet       Date:  1974-12-28       Impact factor: 79.321

6.  Studies on the mechanism of liver injury by antibody-dependent cell-mediated cytotoxicity (ADCC)--partial purification of cytotoxic factor detected in the culture supernatant of ADCC reaction.

Authors:  Y Mizoguchi; T Monna; S Yamamoto; S Morisawa
Journal:  Gastroenterol Jpn       Date:  1982

7.  Purification and characterization of human liver-specific membrane lipoprotein (LSP).

Authors:  I G McFarlane; B M Wojcicka; G M Zucker; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

8.  Possible involvement of macrophage-mediated hepatocytotoxicity in chronic active hepatitis: the induction of liver cell injury by culture supernatant of MAF-activated macrophages.

Authors:  Y Mizoguchi; T Shiba; F Ohnishi; T Monna; S Yamamoto; K Nakai; S Otani; S Morisawa
Journal:  Hepatogastroenterology       Date:  1981-10

9.  Immunological studies on chronic active hepatitis: possible involvement of macrophage-mediated cytotoxicity in its immunopathogenesis.

Authors:  Y Mizoguchi; T Shiba; F Ohnishi; T Monna; S Yamamoto; S Morisawa
Journal:  Hepatogastroenterology       Date:  1981-10

10.  Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis.

Authors:  D M Jensen; I G McFarlane; B S Portmann; A L Eddleston; R Williams
Journal:  N Engl J Med       Date:  1978-07-06       Impact factor: 91.245

View more
  1 in total

1.  Glycyrrhizin ameliorates metabolic syndrome-induced liver damage in experimental rat model.

Authors:  Rajarshi Sil; Doel Ray; Abhay Sankar Chakraborti
Journal:  Mol Cell Biochem       Date:  2015-09-23       Impact factor: 3.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.